Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

62°

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.425 +0.015 (+1.06%)

Streaming Delayed Price Updated: 1:44 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >

Earnings Preview: INmune Bio ↗

March 01, 2023

Via Benzinga

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

February 21, 2023

From INmune Bio, Inc.

Via GlobeNewswire

Dow Jumps 250 Points; US Jobless Claims Increase Last Week ↗

February 09, 2023

U.S. stocks traded higher this morning, with the Dow Jones jumping around 250 points on Thursday. The Dow traded up 0.75% to 34,204.99 while the NASDAQ rose 1.15% to 12,047.28. The S&P 500 also rose,...

Via Benzinga

Nasdaq Tumbles 150 Points; Crude Oil Up 1.5% ↗

February 08, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 150 points on Wednesday. The Dow traded down 0.27% to 34,063.42 while the NASDAQ fell 1.33% to 11,952.51. The...

Via Benzinga

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom

February 08, 2023

From INmune Bio, Inc.

Via GlobeNewswire

What to Know About the Future of Cancer Treatment

January 31, 2023

Via StatePoint Media

INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines ↗

October 19, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 25, 2023

Via Benzinga

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

January 25, 2023

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease

December 22, 2022

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™

December 08, 2022

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

December 06, 2022

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

November 29, 2022

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease

November 14, 2022

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

October 26, 2022

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

October 19, 2022

From INmune Bio, Inc.

Via GlobeNewswire

Recap: INmune Bio Q2 Earnings ↗

August 03, 2022

INmune Bio (NASDAQ:INMB) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings INmune Bio beat estimated...

Via Benzinga

71 Biggest Movers From Yesterday ↗

May 25, 2022

Gainers CynergisTek, Inc. (NYSE: CTEK) shares surged 100% to close at $1.18 on Tuesday after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 24, 2022

Via Benzinga

50 Stocks Moving In Tuesday's Mid-Day Session ↗

May 24, 2022

Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7 million.

Via Benzinga

The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures ↗

May 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022 ↗

May 24, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

A Preview Of INmune Bio's Earnings ↗

May 04, 2022

INmune Bio (NASDAQ:INMB) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that INmune Bio will...

Via Benzinga

60 Biggest Movers From Yesterday ↗

April 26, 2022

Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data from independent dose finding studies of its two...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

April 25, 2022

Gainers Nkarta, Inc. (NASDAQ: NKTX) shares jumped 108.6% to $16.21 after the company announced Phase 1 data from independent dose finding studies of its two lead chimeric antigen...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

63 Biggest Movers From Yesterday ↗

March 25, 2022

Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet...

Via Benzinga

34 Stocks Moving In Thursday's Mid-Day Session ↗

March 24, 2022

Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 37.7% to $4.64. Emclaire Financial Corp (NASDAQ: EMCF) shares climbed 32.8% to $38.35 after the company and...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 16, 2022

Gainers

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: vctr@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

INmune Bio Inc. - Common stock (NQ:INMB)

All News about INmune Bio Inc. - Common stock

Sections

Services

Follow Us